{"id":"budesonide-formoterol-turbuhaler","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is an inhaled corticosteroid that suppresses inflammatory mediators and immune cell recruitment in the airways. Formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, providing sustained bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance and reliever therapy in asthma and COPD.","oneSentence":"Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:42.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance and reliever therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT05202262","phase":"PHASE3","title":"A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-01-12","conditions":"Asthma","enrollment":645},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT04705727","phase":"PHASE3","title":"Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2021-08-23","conditions":"Asthma in Children","enrollment":102},{"nctId":"NCT03691961","phase":"NA","title":"Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair)","status":"UNKNOWN","sponsor":"Hopital Foch","startDate":"2018-09-20","conditions":"Asthma","enrollment":24},{"nctId":"NCT04215848","phase":"PHASE3","title":"As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2020-04-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT04078126","phase":"PHASE3","title":"Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":35},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT02497001","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-08-10","conditions":"COPD","enrollment":1902},{"nctId":"NCT01787097","phase":"PHASE4","title":"Effect of Symbicort ® on GR in Sputum in COPD","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"Chronic Obstructive Lung Disease","enrollment":31},{"nctId":"NCT03114969","phase":"","title":"Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":450},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT03262012","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-08-09","conditions":"COPD","enrollment":416},{"nctId":"NCT02833480","phase":"PHASE2","title":"A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":69},{"nctId":"NCT02224157","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-28","conditions":"Asthma","enrollment":4215},{"nctId":"NCT02149199","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-07","conditions":"Asthma","enrollment":3850},{"nctId":"NCT02766608","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-05-31","conditions":"Chronic Obstructive Pulmonary Disorder","enrollment":2389},{"nctId":"NCT01415518","phase":"PHASE4","title":"Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":581},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT03563001","phase":"PHASE4","title":"Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome, Small Airway Disease","enrollment":80},{"nctId":"NCT03551197","phase":"PHASE4","title":"Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2018-06-13","conditions":"Pulmonary Disease, Chronic Obstructive, Exercise, Lung Function Decreased","enrollment":50},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT02233803","phase":"PHASE4","title":"A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-14","conditions":"Asthma","enrollment":239},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT02725242","phase":"PHASE3","title":"Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2016-03","conditions":"Asthma","enrollment":77},{"nctId":"NCT03073057","phase":"PHASE1","title":"Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2016-01","conditions":"Asthma","enrollment":20},{"nctId":"NCT01713075","phase":"","title":"Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1183},{"nctId":"NCT01711840","phase":"","title":"Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11","conditions":"Bronchial Asthma","enrollment":2409},{"nctId":"NCT02308098","phase":"PHASE3","title":"To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2014-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT01397890","phase":"PHASE4","title":"Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":793},{"nctId":"NCT01404013","phase":"PHASE4","title":"Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2012-02","conditions":"Asthma","enrollment":99},{"nctId":"NCT01070784","phase":"PHASE3","title":"A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":328},{"nctId":"NCT02093195","phase":"PHASE2","title":"Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2013-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":40},{"nctId":"NCT01232335","phase":"","title":"Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Bronchial Asthma","enrollment":1500},{"nctId":"NCT00624754","phase":"PHASE2","title":"Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-03","conditions":"Obstructive Airway Disease","enrollment":32},{"nctId":"NCT00839800","phase":"PHASE3","title":"Study to Investigate the Efficacy of Symbicort® SMART.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Asthma","enrollment":2091},{"nctId":"NCT01668121","phase":"PHASE1","title":"Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2012-08","conditions":"Asthma","enrollment":48},{"nctId":"NCT01593826","phase":"PHASE1","title":"Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2012-05","conditions":"Asthma","enrollment":72},{"nctId":"NCT00496470","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":660},{"nctId":"NCT01069289","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1293},{"nctId":"NCT01646424","phase":"","title":"Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":446},{"nctId":"NCT01627158","phase":"PHASE1","title":"Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2012-06","conditions":"Asthma","enrollment":72},{"nctId":"NCT01257048","phase":"EARLY_PHASE1","title":"Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation","enrollment":34},{"nctId":"NCT00542880","phase":"PHASE4","title":"Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":442},{"nctId":"NCT00489853","phase":"PHASE4","title":"Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":137},{"nctId":"NCT00837967","phase":"PHASE3","title":"Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":"Asthma","enrollment":25},{"nctId":"NCT00536731","phase":"PHASE3","title":"Symbicort Rapihaler Therapeutic Equivalence Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Bronchial Asthma","enrollment":742},{"nctId":"NCT00989833","phase":"PHASE2","title":"Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Exercise Induced Asthma","enrollment":66},{"nctId":"NCT00628758","phase":"PHASE3","title":"A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Asthma","enrollment":430},{"nctId":"NCT01179152","phase":"NA","title":"Study of Preventive Treatment With Symbicort or Budicort Turbohaler in Childhood Asthma Return to School Epidemic","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2010-09","conditions":"Asthma Exacerbation","enrollment":225},{"nctId":"NCT00569712","phase":"PHASE1","title":"Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and Formoterol","status":"COMPLETED","sponsor":"British Columbia Cancer Agency","startDate":"2007-01","conditions":"Lung Cancer, Precancerous Condition","enrollment":30},{"nctId":"NCT01457716","phase":"NA","title":"Pharmacokinetic Pilot Study on Budesonide/Formoterol","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2011-10","conditions":"Healthy","enrollment":17},{"nctId":"NCT00939341","phase":"PHASE4","title":"Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Asthma","enrollment":862},{"nctId":"NCT00812357","phase":"","title":"Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-04","conditions":"Asthma","enrollment":579},{"nctId":"NCT01386996","phase":"PHASE1","title":"Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2011-07","conditions":"Asthma","enrollment":74},{"nctId":"NCT01232348","phase":"","title":"Symbicort Turbuhaler 30/60 Clinical Experience Investigation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Bronchial Asthma","enrollment":3643},{"nctId":"NCT01181063","phase":"PHASE1","title":"Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2010-08","conditions":"Asthma","enrollment":20},{"nctId":"NCT00272753","phase":"PHASE4","title":"Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":"Asthma","enrollment":20},{"nctId":"NCT00837629","phase":"","title":"Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":743},{"nctId":"NCT00379028","phase":"PHASE4","title":"Airway Clearance Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT00242775","phase":"PHASE3","title":"Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Asthma","enrollment":2100},{"nctId":"NCT00252785","phase":"PHASE3","title":"Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Asthma","enrollment":340},{"nctId":"NCT00244608","phase":"PHASE3","title":"A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Asthma","enrollment":100},{"nctId":"NCT00687310","phase":"PHASE4","title":"Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) Trial","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Asthma","enrollment":160},{"nctId":"NCT00259779","phase":"PHASE3","title":"Comparison Between Symbicort® and Prednisolone in COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":120},{"nctId":"NCT00235911","phase":"PHASE3","title":"Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Asthma","enrollment":100},{"nctId":"NCT00252824","phase":"PHASE3","title":"STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00326053","phase":"PHASE3","title":"Prevention of Asthma Relapse After Discharge From Emergency","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Asthma","enrollment":600},{"nctId":"NCT00658255","phase":"PHASE2","title":"Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-10","conditions":"Stable Asthma","enrollment":175},{"nctId":"NCT00242411","phase":"PHASE4","title":"MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Asthma","enrollment":1900},{"nctId":"NCT00812682","phase":"","title":"Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Perception of Physicians & Patients of AMD","enrollment":217},{"nctId":"NCT00288379","phase":"PHASE3","title":"SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-10","conditions":"Asthma","enrollment":16},{"nctId":"NCT00259792","phase":"PHASE3","title":"SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00255255","phase":"PHASE3","title":"Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-11","conditions":"Asthma","enrollment":120},{"nctId":"NCT00385593","phase":"PHASE3","title":"Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Asthma, Bronchial","enrollment":654},{"nctId":"NCT00576316","phase":"PHASE4","title":"Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Asthma","enrollment":201},{"nctId":"NCT00503061","phase":"","title":"A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Bronchial Asthma","enrollment":1000},{"nctId":"NCT00419744","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1200},{"nctId":"NCT00868426","phase":"PHASE1","title":"Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2009-04","conditions":"Healthy","enrollment":12},{"nctId":"NCT00782314","phase":"","title":"Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Asthma","enrollment":400},{"nctId":"NCT00523679","phase":"","title":"Symbicort SMART (Symbicort Maintenance And Reliever Therapy)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-07","conditions":"Asthma","enrollment":2000},{"nctId":"NCT00532922","phase":"","title":"A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-04","conditions":"Asthma","enrollment":310},{"nctId":"NCT00646529","phase":"PHASE3","title":"Long-Term Safety of Symbicort in Asthmatic Children - SAPLING","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-07","conditions":"Asthma","enrollment":175},{"nctId":"NCT00206154","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1500},{"nctId":"NCT00421122","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":315},{"nctId":"NCT00206167","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1600},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600},{"nctId":"NCT00557297","phase":"","title":"NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Asthma","enrollment":250},{"nctId":"NCT00728715","phase":"NA","title":"Efficacy of Budesonide-Formoterol in Bronchiectasis","status":"COMPLETED","sponsor":"Hospital General de Requena","startDate":"2004-01","conditions":"Bronchiectasis","enrollment":40},{"nctId":"NCT00238784","phase":"PHASE3","title":"SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05","conditions":"Asthma","enrollment":1300}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"EXPIRED DRUG ADMINISTERED"},{"count":2,"reaction":"PRODUCT QUALITY ISSUE"},{"count":1,"reaction":"DEVICE FAILURE"},{"count":1,"reaction":"DEVICE MALFUNCTION"}],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Symbicort"],"phase":"marketed","status":"active","brandName":"Budesonide/formoterol Turbuhaler","genericName":"Budesonide/formoterol Turbuhaler","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}